On Nov 07, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals (JAZZ.US)$, with price targets ranging from $140 to $207.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $140.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $172 to $182.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $200 to $190.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $200 to $195.
Needham analyst Ami Fadia maintains with a buy rating, and adjusts the target price from $205 to $207.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals reported third-quarter revenue in line with expectations and a significant beat on non-GAAP net income, despite facing temporary challenges affecting the Rylaze brand. The overall assessment of the third-quarter results is positive. The company is perceived to be trading at very low multiples, yet is projected to deliver mid-single digit revenue growth and high-single digit earnings growth on an annual compound basis.
Jazz Pharmaceuticals' Q3 revenue surpassed expectations, primarily due to robust performance from its main growth contributors Xywav and Epidiolex. However, Rylaze experienced a temporary setback due to changes in the treatment protocol.
Jazz Pharmaceuticals' total Q3 revenue surpassed expectations, bolstered by strong performances from products including Xywav, Epidiolex, Defitelio, and Zepzelca.
Here are the latest investment ratings and price targets for $Jazz Pharmaceuticals (JAZZ.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$爵士製藥 (JAZZ.US)$的評級，目標價介於140美元至207美元。
摩根士丹利分析師Jeffrey Hung維持持有評級，維持目標價140美元。
美銀證券分析師Jason Gerberry維持買入評級，並將目標價從172美元上調至182美元。
巴克萊銀行分析師Balaji Prasad維持買入評級，並將目標價從200美元下調至190美元。
TD Cowen分析師Joseph Thome維持買入評級，並將目標價從200美元下調至195美元。
Needham分析師Ami Fadia維持買入評級，並將目標價從205美元上調至207美元。
此外，綜合報道，$爵士製藥 (JAZZ.US)$近期主要分析師觀點如下：
爵士製藥報告稱，第三季度營業收入符合預期，非通用會計淨利潤顯著優於預期，儘管受到影響Rylaze品牌的暫時性挑戰。第三季度業績整體評估爲積極。公司被認爲正在以非常低的倍數交易，但據預測，將以複合年度基礎上交付中單位數的營業收入增長和高單位數的收益增長。
爵士製藥第三季度營收超過預期，主要是由於其主要增長貢獻者Xywav和Epidiolex的強勁表現。然而，由於治療方案的更改，Rylaze遭遇了暫時挫折。
爵士製藥第三季度總營收超過預期，得到Xywav、Epidiolex、Defitelio和Zepzelca等產品的強勁表現支撐。
以下爲今日7位分析師對$爵士製藥 (JAZZ.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
